17:31 EDT ZyVersa Therapeutics files $100M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVSA:
- ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
- ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
- ZyVersa Therapeutics announces publication of data on extracellular ASC
- ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
- ZyVersa Therapeutics announces publication of data on inflammasome ASC